New antibiotic compound enters phase I clinical trial

November 9, 2011, Wellcome Trust
New antibiotic compound enters phase I clinical trial
False colour light micrograph of Clostridium difficile. Credit: Derren Ready, Wellcome Images.

(Medical Xpress) -- Novacta Biosystems has commenced dosing of the first healthy volunteers in a phase I clinical trial of a new antibiotic to treat the hospital superbug Clostridium difficile.

Laboratory studies have shown that the new compound, NVB302, is effective against all strains of difficile tested, without adversely affecting the healthy bacteria that are normally found in the gut.

Developed with support from a Wellcome Trust Strategic Translation Award, NVB302 is now being tested in a first-in-man trial to determine the safety and tolerability of the compound in healthy volunteers.

C. difficile is a hospital-acquired infection that causes severe and can be life threatening, particularly for the elderly. Few currently available are effective against C. difficile infection and is a growing threat.

Ted Bianco, Director of Technology Transfer at the Wellcome Trust, said: "C. difficile is a particularly insidious infection that catches people at their most vulnerable. With the ever-present threat of increasing drug resistance, taking this new antibiotic into is a significant step on the road to replenishing our depleted medicine cabinet."

NVB302 is a member of a class of antibiotics known as the type B lantibiotics, a naturally occurring class of antibiotic compounds found in many bacteria. Lantibiotics have shown great potential to treat superbug infections such as C. difficile and MRSA; however, conventional has not been able to optimise the structure of the naturally occurring compounds into a form with the potential to treat human disease.

Novacta's proprietary technologies have allowed the structural manipulation and optimisation of the lantibiotics' , to unlock the potential of this novel and underexploited class of compounds.

"We are very pleased to announce the initiation of clinical studies with NVB302," said Dr Mike Dawson, Chief Scientific Officer of Novacta. "This is a major milestone for the company."

Dr Richard Garraway, a Partner in CPHA and member of the Novacta Board of Directors, added: "Celtic is delighted that Novacta has achieved this significant milestone. We are committed to supporting the company through this clinical programme and to work with Novacta in securing an attractive partner for the late-stage clinical development and commercialisation of NVB302."

Explore further: Hope for powerful new C diff. treatment

Related Stories

Hope for powerful new C diff. treatment

September 19, 2011
MGB Biopharma, a biopharmaceutical company which has licensed technology from the University of Strathclyde in Glasgow, Scotland, is developing a powerful new antibiotic treatment for resistant infections including the deadly ...

Hospital superbug debugged

October 13, 2011
An international team of scientists led by Monash University researchers has uncovered how a common hospital bacterium becomes a deadly superbug that kills increasing numbers of hospital patients worldwide and accounts for ...

Recommended for you

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

Less is more when it comes to prescription opioids for hospital patients, study finds

May 14, 2018
In a pilot study published in JAMA Internal Medicine, Yale researchers significantly reduced doses of opioid painkillers given to hospital patients. By delivering the opioids with a shot under the skin or with a pill instead ...

Generic options provide limited savings for expensive drugs

May 7, 2018
Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released today in its May issue.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.